Compared to existing methods, our approach offers three distinct advantages: first, HAB-MIL accurately identifies subtle imaging differences between IDH wild-type and lDH-mutant gliomas through key instance selection, helping clinicians pinpoint regions that are most informative for distinguishing IDH status. This evidence concerns the gene IDH1 and central nervous system cancer.